Financial Reports
Latest Updates
Takeda Pharmaceutical Company Limited (4502) Earnings Releases & Disclosures
| Date | Type | Title | Files |
|---|---|---|---|
| 2026-08-06 | — | U.S. FDA Approves Takeda’s ORZEYFUL (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 | |
| 2026-07-30 | 決算短信 | Earnings Report (Kessan Tanshin) for the Three-month Period Ended June 30, 2026 (IFRS, Consolidated) |
TDnet keeps only 31 days; this site accumulates daily and cannot backfill earlier disclosures.